Skip to main content

Table 2 Patient characteristics

From: Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

Characteristic Patients
  (N = 72)
Age, years  
Median (SD) 58.0 (12.4)
Range 23–78
Gender, n (%)  
Male 36 (50.0)
Female 36 (50.0)
ECOG PS, n (%)  
0 22 (31)
1 49 (68)
Not recorded 1 (1)
Tumor type, n (%)  
NSCLC 13 (18.0)
Breast 10 (13.8)
Melanoma 6 (8.3)
Pancreas 5 (6.9)
Prostate 4 (5.6)
Colon 4 (5.6)
Esophagus 3 (4.2)
Parotid 3 (4.2)
SCLC 3 (4.2)
Othera 21 (29.2)
  1. Abbreviations: SD standard deviation, ECOG Eastern Cooperative Oncology Group, PS performance status, SCLC small cell lung cancer, SCC squamous cell cancer.
  2. aCervical, cholangiocarcinoma, gastric, mesothelioma, endothelial cell, bladder, renal, sarcoma, SCC orbit, SCC vagina, SCC vulva, anal, tonsil, hard palate, and vulva.